Key result
CLTI is linked to ~6.4-fold higher risk of patency loss after femoropopliteal stenting.
Why the study?
Restenosis necessitating reintervention remains a challenge after femoropopliteal stenting in patients with PAD, and it was unclear which patient populations might benefit from a Doppler ultrasound surveillance program to improve primary patency and amputation-free survival.
Cohort (n=220)
Yes
Long-term primary patency after femoropopliteal stenting is low (11.7% at 5 years), and patients with chronic limb-threatening ischemia, type 1 diabetes, or female sex are at significantly higher risk of patency loss and may benefit from enhanced Doppler ultrasound surveillance.
Answers are grounded in this paper and cite their sources.
CLTI may warrant closer post-stenting surveillance; leaves open whether routine Doppler monitoring improves patency or survival.
BACKGROUND: Peripheral arterial disease (PAD) is a significant global health concern. Endovascular revascularization is frequently used for symptom control and limb salvage in patients with femoropopliteal PAD. However, restenosis, often necessitating reintervention, remains a challenge. This study performs a retrospective outcomes analysis to suggest which patient populations may benefit from a Doppler ultrasound (DUS) surveillance program in improving primary patency and amputation-free survival following femoropopliteal stenting in patients with PAD. METHODS: A multicenter, retrospective cohort study was conducted using data from patients who underwent femoropopliteal stenting between January 2015 and April 2023 within a vascular network with 6 hospital sites. Data were collected from 238 stents in 220 patients. Demographics, stent characteristics, and surveillance protocols were analyzed. Cox proportional hazards and logistic regression models were used to identify risk factors for primary patency and amputation-free survival. Kaplan-Meier survival curves were generated for both outcomes. Descriptive statistics were used to compare outcomes between suprapopliteal and infrapopliteal stents. RESULTS: A total of 238 stents were inserted in a population in which 28.6% were women, with the median age of 72.5 ± 11.5 years. In 74.8% (178) of cases, patients presented with chronic limb-threatening ischemia (CLTI). Primary patency rates at 30 days, 6 months, 1 year, 3 years, and 5 years were 90%, 67.7%, 51.2%, 26.6%, and 11.7%, respectively. The average amputation-free survival was 3.2 years. Cox regression identified CLTI (hazard ratio, 6.37, P = 0.001), type 1 diabetes mellitus (hazard ratio, 3.16, P = 0.006), and female sex (hazard ratio, 1.69, P = 0.037) as significant predictors of loss of primary patency. Drug-eluting stents and diabetes were associated with poorer amputation-free survival. CONCLUSION: The study illustrates a cohort of high-risk patients, particularly those with CLTI and diabetes, who may benefit from future enrollment in an enhanced DUS surveillance program targeted to improve long-term outcomes. However, further research is required to explore the clinical effectiveness, cost-effectiveness, and implementation feasibility of such programs in clinical practice.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2026) conducted a cohort in Peripheral arterial disease undergoing femoropopliteal stenting (n=220). Femoropopliteal stenting was evaluated on Primary patency and amputation-free survival (HR 6.37, p=0.001). Femoropopliteal stenting achieved 51.2% 1-year and 11.7% 5-year primary patency, with CLTI strongly predicting patency loss.
Synapse has enriched 10 related papers. Consider them for comparative context: